Table 1 Correlation between HOXD9 protein expression and the clinicopathological parameters of gastric carcinoma
Features | Total number (n = 90) | HOXD9 Expression | P | |
|---|---|---|---|---|
Low | High | |||
Age (years) | ||||
 <60 | 35 | 12 (34.3%) | 23 (65.7%) | 0.475 |
 ≥60 | 55 | 23 (41.8%) | 32 (58.2%) | |
Gender | ||||
 Male | 53 | 23 (43.3%) | 30 (56.6%) | 0.294 |
 Female | 37 | 12 (32.4%) | 25 (67.6%) | |
Differentiation | ||||
 Well | 29 | 22 (75.9%) | 7 (24.1%) | <0.001 |
 Moderate | 17 | 8 (47.1%) | 9 (52.9%) | |
 Poor | 44 | 5 (5.6%) | 39 (88.6%) | |
Lymph node metastasis | ||||
 Yes | 67 | 15 (22.4%) | 52 (77.6%) | <0.001 |
 No | 23 | 20 (87.0%) | 3 (13.0%) | |
Tumor size (cm3) | ||||
 <10 | 24 | 16 (66.7%) | 8 (33.3%) | 0.001 |
 ≥10 | 66 | 19 (28.8%) | 47 (52.2%) | |
AJCC stage | ||||
 T1, T2 | 14 | 11 (78.6%) | 3 (21.4%) | 0.001 |
 T3, T4 | 76 | 24 (31.6%) | 52 (68.4%) | |
AJCC TNM stage | ||||
 I, II | 36 | 27 (75.0%) | 9 (25.0%) | <0.001 |
 III, IV | 54 | 8 (14.8%) | 46 (85.2%) | |